MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.
By M. Awad, G. Oxnard, D. Jackman, Daniel O Savukoski, Dimity L Hall, Priyanka Shivdasani, J. Heng, S. Dahlberg, P. Jänne, Suman Verma and 3 more. Journal of Clinical Oncology, 2016
640 citations recorded by the source corpus.
Subfields: Hepatology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/63e4b99a551c5b6051e8d2ab1eb946039d127902
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hepatology
In Pulmonary and Respiratory Medicine
Citations in the corpus
- Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology (2018, background): “Importantly, about 20% of lung adenocarcinomas with MET exon 14–skipping mutations have concurrent high-level MET amplification, confounding the interpretation of each.(125,126,129)”